The WACC of Olema Pharmaceuticals Inc (OLMA) is 8.7%.
Range | Selected | |
Cost of equity | 11.9% - 15.6% | 13.75% |
Tax rate | 26.2% - 27.0% | 26.6% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 7.8% - 9.6% | 8.7% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 1.75 | 1.92 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 11.9% | 15.6% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 1 | 1 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 7.8% | 9.6% |
Selected WACC | 8.7% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
OLMA | Olema Pharmaceuticals Inc | 1.14 | 1.9 | 1.04 |
ALEC | Alector Inc | 0.07 | 1.94 | 1.84 |
ARQT | Arcutis Biotherapeutics Inc | 0.07 | 0.83 | 0.79 |
DMTK | DermTech Inc | 0.03 | 2.09 | 2.05 |
KURA | Kura Oncology Inc | 0.02 | 1.37 | 1.35 |
MRNA | Moderna Inc | 0.01 | 0.95 | 0.94 |
OCGN | Ocugen Inc | 0.12 | 1.39 | 1.28 |
QURE | Uniqure NV | 0.61 | 1.64 | 1.13 |
REPL | Replimune Group Inc | 0.1 | 1.92 | 1.79 |
VBIV | VBI Vaccines Inc | 13.32 | 1.21 | 0.11 |
ZYME | Zymeworks Inc | 0 | 1.39 | 1.39 |
Low | High | |
Unlevered beta | 1.13 | 1.35 |
Relevered beta | 2.12 | 2.37 |
Adjusted relevered beta | 1.75 | 1.92 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for OLMA:
cost_of_equity (13.75%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (1.75) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.